CLONAL SELECTION OF CD20-NEGATIVE NON-HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI-CD20 ANTIBODY RITUXIMAB
نویسندگان
چکیده
منابع مشابه
[Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma].
Nehočkinski limfomi (NHL) predstavljaju heterogenu grupu limfoidnih neoplazmi uglavnom porekla od B limfocita (85%). Normalni limfociti, kao nosioci imuniteta, neprekidno primaju signale smrti i preživljavanja, a njihov balans obezbeđuje „limfocitnu homeostazu“ i sprečava autoimunitet. Iz još uvek nedovoljno utvrđenih razloga, nastanak funkcijske disregulacije ovih ćelija vodi ka neoplastičnoj ...
متن کاملAnti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
BACKGROUND Pemphigus is a severe autoimmune blistering disorder caused by autoantibodies to desmoglein 1 and 3. The disease course is typically severe, thus requiring multiple immunosuppressive agents. The treatment is still challenging and in some patients with recalcitrant disease, therapies fail and therapeutic options are limited. OBJECTIVES To investigate whether depletion of B lymphocyt...
متن کاملAnti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.
Incubation of Burkitt lymphoma-derived Raji cells at physiological temperature with submicromolar concentrations of humanized anti-CD20 antibody rituximab (RTX) redistributes CD20 to liquid-ordered, plasma membrane rafts. This accumulation of the CD20 tetraspan protein in rafts does not change the existing lipid and phosphoprotein composition but makes sphingolipids and the Src regulator Cbp/PA...
متن کاملTreatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
BACKGROUND Rituximab, a chimeric monoclonal anti-CD20 antibody, has recently been used for the treatment of refractory antibody mediated autoimmune diseases such as immune mediated thrombocytopenia and haemolytic anaemia. PATIENTS Because of its novel mechanism of action, rituximab was used to treat three patients with refractory systemic antibody mediated autoimmune disorders. The first pati...
متن کاملRituximab and Other New Anti-cd20 Mabs for Non-hodgkin’s Lymphoma Treatment
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells. CD20 represents a good target for NHL immunotherapy because it is largely expressed on B cell NHL and not on B cell precursors and plasma cells. The anti-CD20 monoclonal antibody (mAb) rituxim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 1999
ISSN: 0007-1048
DOI: 10.1046/j.1365-2141.1999.01608.x